平消胶囊与参丹散结胶囊辅助培美曲塞联合卡铂治疗Ⅳ期非小细胞肺癌的疗效比较.PDFVIP

平消胶囊与参丹散结胶囊辅助培美曲塞联合卡铂治疗Ⅳ期非小 细胞肺癌的疗效比较 ＊ 王蜀梅 ，李 钧（山西省肿瘤医院，太原 030013） 中图分类号 R453.9 文献标志码 A 文章编号 1001-0408（2015）30-4200-03 DOI 10.6039/j.issn.1001-0408.2015.30.08 摘 要 目的：比较平消胶囊与参丹散结胶囊辅助培美曲塞联合卡铂（CP 方案）治疗Ⅳ期非小细胞肺癌（NSCLC ）的疗效和安全 性。方法：132例Ⅳ期NSCLC 患者随机均分为CP 组、CP+平消组、CP+参丹散结组。CP 组患者给予CP 方案治疗；在此基础上， CP+平消组患者给予平消胶囊6粒，口服，每日3次；CP+参丹散结组患者给予参丹散结胶囊6粒，口服，每日3次。各组患者均治 疗21d 为1个周期，连续治疗2个周期后评价近期疗效，观察各组患者生存质量改善情况、无进展生存期、1年生存率及毒副反 应。结果：CP+平消组、CP+参丹散结组患者近期有效率、疾病控制率、生存质量总改善率、无进展生存期、1年生存率均显著高于 CP 组，白细胞减少、血小板减少、消化道反应、血红蛋白下降发生率均显著低于CP 组，差异均有统计学意义（P ＜0.05）；但CP+平消 组、CP+参丹散结组两组间比较差异均无统计学意义（P ＞0.05）。结论：平消胶囊、参丹散结胶囊均可辅助CP 方案治疗Ⅳ期 NSCLC ，近期疗效和安全性较单用CP 方案好。 关键词 平消胶囊；参丹散结胶囊；培美曲塞；卡铂；Ⅳ期非小细胞肺癌 Comparison of the Efficacy of Pingxiao Capsule and Shendan Sanjie Capsule Combined with CP Program in the Treatment of Non-small Cell Lung Cancer in Stage Ⅳ WANG Shu-mei ，LI Jun （Shanxi Tumor Hospital ，Taiyuan 030013，China ） ABSTRACT OBJECTIVE ：To compare the efficacy and safety of Pingxiao capsule and Shendan Sanjie capsule combined with CP program in the treatment of non-small cell lung cancer （NSCLC ）in stage Ⅳ. METHODS ：132NSCLC patients in stage Ⅳ were randomly divided into CP group ，CP+Pingxiao group and CP+Shendan Sanjie group. CP group was treated with CP program ； based on it ，CP+Pingxiao group was orally treated with 6 Pingxiao capsules ，3times a day ；CP+Shendan Sanjie group was orally treated with 6 Shendan Sanjie capsules ，3 times a day. 21 d was a treatment period ，and the efficacy was evaluated after 2 treat- ment periods ，improvement of life quality ，progression-free survival ，1-year survival rate and toxicity reactions were observed. RE- SULTS ：The recent effective rate ，disease control rate ，total improvement rate of life quality ，progression-free survival and 1-year survival rate in CP+Pingxiao group and CP+Shendan Sanjie group were significantly higher than